In order to provide faster identification of bloodstream pathogens, bioMérieux (Euronext: BIM) has agreed with AdvanDx, Inc. to sign an exclusive distribution agreement for the United States for AdvanDx’s PNA FISH™ rapid diagnostic tests. These tests will be displayed at bioMérieux’s booth from the opening of the American Society of Microbiology (ASM) in Toronto on May 22.
Nachrichten
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
04 Mai, 2022Joint infections (“septic arthritis”) are serious infections involving either native or prosthetic joints. They are medical emergencies which can occur at all ages, and can lead to functional joint impairment, long-lasting disability, and may even be life-threatening. The number of prosthetic...
bioMérieux Launches a Molecular Biology Test for the Detection of HPV, a Major Cause of Cervical Cancer
23 April, 2007
bioMérieux (Euronext: BIM) announces the launch of its NucliSENS EasyQ® HPV; this molecular diagnostic test enables the detection of human papillomavirus (HPV) in cervical cancer surveillance.
bioMérieux and LabTech Systems sign exclusive worldwide license agreement for innovative robotic microbiological instrumentation
18 April, 2007
LabTech Systems Ltd (ASX: LBT), an Australian health care equipment and services company, and bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, announced today that they have signed an exclusive worldwide license agreement for LabTech Systems’ automated pre-poured media (PPM) streaker known as MicroStreak®.
bioMérieux Launches VIDAS® B·R·A·H·M·S PCT, a Procalcitonin Measurement Test Allowing Early Detection of Severe Bacterial Infections
30 März, 2007
bioMérieux, a global leader in the field of in vitro diagnostics, today announces the launch of VIDAS® B·R·A·H·M·S PCT. This new, CE approved test, was developed following the licensing agreement signed with B·R·A·H·M·S, enabling bioMérieux to develop, produce and market a test for measuring procalcitonin (PCT) levels. The test is sensitive and specific, used in the early detection of severe bacterial infections (e.g. sepsis).
bioMérieux Receives Major Order from BML, Japan’s Biggest Laboratory Chain
06 März, 2007
bioMérieux, a global leader in the field of in vitro diagnostics, announces today that it has received a major order from BML, Inc. (BioMedical Laboratories), the biggest Japanese private laboratory chain. bioMérieux will supply 28 VITEK® 2 XL to BML.
bioMérieux confirms its commitment to the fight against Hospital Acquired Infections
15 Februar, 2007
bioMérieux, a global leader in the field of in vitro diagnostics, confirms its commitment to the fight against Hospital Acquired Infections with the launch of three new products.
bioMérieux and ExonHit Therapeutics initiate their third diagnostic program
04 Januar, 2007
Screening of prostate cancer from blood. bioMérieux and ExonHit Therapeutics announce, today, the initiation of their third programme for the screening of cancer from blood. One of the goals is to assist physicians in deciding whether to proceed with surgery for prostate cancer.
